By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Viralytics Ltd 

66 Hunter Street, Suite 305, Level 3

  Sydney  2000  Australia
Phone: 61-2-8889-3671 Fax: 61-2-8068-6038


SEARCH JOBS


Industry
Biotechnology






Company News
Viralytics Ltd (VLA.AX) Release: CAVATAK Increases Anti-Cancer Immune Activity In The Tumor Micro-environment 4/19/2016 10:13:01 AM
Viralytics Ltd (VLA.AX) Release: Positive Clinical Data From CAVATAK And YERVOY Combination Presented At The 2016 AACR Annual Meeting 4/19/2016 10:07:13 AM
Combinations Of Viralytics Ltd (VLA.AX) CAVATAK And Checkpoint Immunotherapy Demonstrate Anti-Cancer Activity In Preclinical Lung Cancer And Melanoma Studies 4/19/2016 10:04:09 AM
Viralytics Ltd (VLA.AX) Release: Positive CAVATAK Clinical Data Presented At 2016 European Association Of Urology Congress 3/15/2016 9:02:19 AM
Viralytics Ltd (VLA.AX) Completes $28 Million Placement -- SPP To Follow 12/14/2015 11:13:52 AM
Viralytics Ltd (VLA.AX) Completes $28 Million Placement -- SPP To Follow 12/14/2015 6:42:49 AM
Viralytics Ltd (VLA.AX) Release: Positive CAVATAKTM Clinical Data Presented At 2015 Society For Immunotherapy Of Cancer (SITC) Meeting 11/9/2015 12:50:21 PM
Viralytics Ltd (VLA.AX) And Merck & Co. (MRK), Kenilworth, New Jersey, U.S.A. To Collaborate On Combination Clinical Trial Of CAVATAK And KEYTRUDA In Lung And Bladder Cancer 11/6/2015 6:34:59 AM
Viralytics Ltd (VLA.AX) Initiates Clinical Trial Of CAVATAK In Combination With PD-1 Blocker Keytruda 9/28/2015 9:57:37 AM
Viralytics Ltd (VLA.AX) Presents Phase 2 Melanoma Extension Cohort Data, Updated CALM Study Survival And CAVATAK/Immune Checkpoint Combination Preclinical Data At 2015 European Cancer Congress 9/28/2015 9:55:32 AM
1234
//-->